表紙
市場調査レポート

多発性硬化症の米国市場:2015-2019年

Multiple Sclerosis Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 335164
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
多発性硬化症の米国市場:2015-2019年 Multiple Sclerosis Market in the US 2015-2019
出版日: 2015年07月08日 ページ情報: 英文 104 Pages
概要

米国の多発性硬化症市場は、2014年から2019年の間、3.8%のCAGRで拡大する見込みです。

当レポートでは、米国の多発性硬化症市場について調査し、現在の市況と将来の展望、投与経路・分子タイプ別の分析、主なパイプライン薬、競合情勢、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 提供製品

第4章 製品プロファイル

  • Betaseron/Extavia
  • Avonex/Rebif
  • Tecfidera
  • Tysabri
  • Gilenya
  • Copaxone

第5章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第6章 イントロダクション

第7章 多発性硬化症:概要

  • 疾病について
  • 兆候・症状
  • 病因
  • 疫学
  • 経済的負担

第8章 市場情勢

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 市場区分:投与経路別

  • 経口薬
    • 市場規模・予測
  • 非経口薬

第10章 市場区分:分子タイプ別

  • 小分子
  • 生物製剤

第11章 パイプラインポートフォリオ

  • 後期段階パイプライン分子の主な情報
    • Daclizumab High-yield Process (BIIB019)
    • RPC1063
    • Masitinib
    • Laquinimod
    • Natalizumab
    • Siponimod or BAF312
    • OS-440 (arbaclofen)
    • Ocrelizumab (RG1594)

第12章 購入基準

第13章 市場成長促進因子

第14章 成長促進因子とその影響

第15章 市場の課題

第16章 成長促進因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合状況
    • 主要ニュース
    • M&A
  • 市場シェア分析
    • 米国における多発性硬化症市場の競合状況
    • Biogen
    • Teva Pharmaceutical
    • Novartis
    • Merck Serono
    • Bayer
  • その他・将来の有望ベンダー

第20章 主要ベンダーのプロファイル

  • Bayer
    • 主要データ
    • 事業概要
    • 事業区分:収益別
    • 事業戦略
    • 近年の発展
    • SWOT分析
  • Biogen
  • Merck Serono
  • Novartis
  • Teva Pharmaceutical

第21章 関連レポート

図表リスト

目次
Product Code: IRTNTR6391

About Multiple Sclerosis

Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS.

Technavio's analysts forecast the multiple sclerosis market in the US to grow at a CAGR of 3.8% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis.

On the basis of route of administration of the drugs, the market is grouped into the following categories:

  • Oral
  • Parenteral

On the basis of type of molecule of the drugs, the market is grouped into the following categories:

  • Small Molecules
  • Biologics

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors and competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, the multiple sclerosis market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the multiple sclerosis market in US market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Bayer AG
  • Biogen
  • Merck Serono
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors

  • AB Science
  • Abbvie
  • Acorda Therapeutics
  • Active Biotech
  • Artielle
  • Astellas
  • AstraZeneca
  • Canbex
  • F. Hoffmann-La Roche
  • GeNeuro
  • GlaxoSmithKline
  • Glenmark
  • InnoBioscience Pharmaceuticals
  • Ipsen
  • Mapi-Pharma
  • medDay Pharmaceuticals
  • MediciNova
  • Mitsubishi Tanabe
  • Opexa Therapeutics
  • Osmotica
  • Pfizer
  • Receptos
  • RedHill Biopharma
  • Sanofi
  • Trophos
  • XenoPort

Market Driver

  • Unmet Medical Needs.
  • For a full, detailed list, view our report.

Market Challenge

  • Unknown Disease Etiology.
  • For a full, detailed list, view our report.

Market Trend

  • Introduction of Disease-modifying Drugs.
  • For a full, detailed list, view our report.

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Betaseron/Extavia
    • 04.1.2. Avonex/Rebif
    • 04.1.3. Tecfidera
    • 04.1.4. Tysabri
    • 04.1.5. Gilenya
    • 04.1.6. Copaxone

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Multiple Sclerosis: An Overview

    • 07.1.1. About the Disease
    • 07.1.2. Signs and Symptoms
    • 07.1.3. Etiology
    • 07.1.4. Epidemiology
    • 07.1.5. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Route of Administration

  • 09.1. Multiple Sclerosis Market in US by Oral Drugs
    • 09.1.1. Market Size and Forecast
  • 09.2. Multiple Sclerosis Market in US by Parenteral Drugs
    • 09.2.1. Market Size and Forecast

10. Market Segmentation by Type of Molecule

  • 10.1. Multiple Sclerosis Market in US by Small Molecules
    • 10.1.1. Market Size and Forecast
  • 10.2. Multiple Sclerosis Market in US by Biologics
    • 10.2.1. Market Size and Forecast

11. Pipeline Portfolio

  • 11.1. Key Information of Late-stage Pipeline Molecules
    • 11.1.1. Daclizumab High-yield Process (BIIB019)
    • 11.1.2. RPC1063
    • 11.1.3. Masitinib
    • 11.1.4. Laquinimod
    • 11.1.5. Natalizumab
    • 11.1.6. Siponimod or BAF312
    • 11.1.7. OS-440 (arbaclofen)
    • 11.1.8. Ocrelizumab (RG1594)

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Competitive Landscape of Multiple Sclerosis Market in US
    • 19.2.2. Biogen
    • 19.2.3. Teva Pharmaceutical
    • 19.2.4. Novartis
    • 19.2.5. Merck Serono
    • 19.2.6. Bayer
  • 19.3. Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Bayer
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2014
    • 20.1.4. Business Segmentation by Revenue 2013 and 2014
    • 20.1.5. Geographical Segmentation by Revenue 2014
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Biogen
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Geographical Segmentation by Revenue 2013
    • 20.2.5. Business Strategy
    • 20.2.6. Key Developments
    • 20.2.7. SWOT Analysis
  • 20.3. Merck Serono
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Geographical Segmentation by Revenue 2013
    • 20.3.4. Business Strategy
    • 20.3.5. Recent Developments
    • 20.3.6. SWOT Analysis
  • 20.4. Novartis
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2012 and 2013
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
    • 20.4.9. SWOT Analysis
  • 20.5. Teva Pharmaceutical
    • 20.5.1. Key Facts
    • 20.5.2. Business Overview
    • 20.5.3. Business Segmentation
    • 20.5.4. Revenue by Business Segmentation
    • 20.5.5. Revenue Comparison 2012 and 2013
    • 20.5.6. Revenue Segmentation by Geography
    • 20.5.7. Business Strategy
    • 20.5.8. Key Developments
    • 20.5.9. SWOT Analysis

21. Other Reports in This Series

List Of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Frequency of Types of Multiple Sclerosis
  • Exhibit 3: Etiology of Multiple Sclerosis
  • Exhibit 4: Snapshot of Multiple Sclerosis Market in US
  • Exhibit 5: Multiple Sclerosis Market in US 2014-2019 ($ millions)
  • Exhibit 6: Segmentation of Multiple Sclerosis Market in US by Route of Administration
  • Exhibit 7: Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014
  • Exhibit 8: Multiple Sclerosis Market in US by Oral Drugs 2014-2019 ($ millions)
  • Exhibit 9: Multiple Sclerosis Market in US by Parenteral Drugs 2014-2019 ($ millions)
  • Exhibit 10: Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014 ($ millions)
  • Exhibit 11: Segmentation of Multiple Sclerosis Market in US by Type of Molecule
  • Exhibit 12: Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014
  • Exhibit 13: Multiple Sclerosis Market in US by Small Molecules 2014-2019 ($ millions)
  • Exhibit 14: Multiple Sclerosis Market in US by Biologics 2014-2019 ($ millions)
  • Exhibit 15: Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014 ($ millions)
  • Exhibit 16: Multiple Sclerosis Drugs Under Development
  • Exhibit 17: Multiple Sclerosis Drugs Under Various Developmental Phases
  • Exhibit 18: Major Drivers of Multiple Sclerosis Market in US
  • Exhibit 19: Major Challenges in Multiple Sclerosis Market in US
  • Exhibit 20: Major Trends in Multiple Sclerosis Market in US
  • Exhibit 21: Global Revenues of Top-selling Drugs for Multiple Sclerosis 2014 ($ millions)
  • Exhibit 22: YoY Global Growth of Top-selling Drugs for Multiple Sclerosis 2012-2014 ($ millions)
  • Exhibit 23: Biogen: YoY Global Revenue of Avonex 2011-2014 ($ millions)
  • Exhibit 24: Biogen: Revenue of Avonex in US 2011-2014 ($ millions)
  • Exhibit 25: Biogen: Revenue of Avonex in ROW 2011-2014 ($ millions)
  • Exhibit 26: Biogen: YoY Global Revenue of Tysabri 2011-2014 ($ millions)
  • Exhibit 27: Biogen: Revenue of Tysabri in US 2011-2014 ($ millions)
  • Exhibit 28: Biogen: Revenue of Tysabri in ROW 2011-2014 ($ millions)
  • Exhibit 29: Biogen: Revenue of Plegridy in US and ROW 2014 ($ millions)
  • Exhibit 30: Biogen: Revenue of Tecfidera in US and ROW 2014 ($ millions)
  • Exhibit 31: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ millions)
  • Exhibit 32: Teva Pharmaceutical: Quarter-wise Revenue of Copaxone 2011-2014 ($ millions)
  • Exhibit 33: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ millions)
  • Exhibit 34: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ millions)
  • Exhibit 35: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ millions)
  • Exhibit 36: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ millions)
  • Exhibit 37: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ millions)
  • Exhibit 38: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ millions)
  • Exhibit 39: Merck Serono: Revenue Share of Rebif by Region 2012-2014
  • Exhibit 40: Bayer: YoY Global Revenue of Betaseron 2011-2014 ($ millions)
  • Exhibit 41: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 42: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 43: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 44: Biogen: Business Segmentation by Revenue 2013
  • Exhibit 45: Biogen: Geographical Segmentation by Revenue 2013
  • Exhibit 46: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 47: Novartis: Business Segmentation
  • Exhibit 48: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 49: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 50: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 51: Teva Pharmaceutical: Business Segmentation
  • Exhibit 52: Teva Pharmaceutical: Revenue by Business Segmentation 2013
  • Exhibit 53: Teva Pharmaceutical: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 54: Teva Pharmaceutical: Revenue by Geographical Segmentation 2013
Back to Top